Ad
CBAY - CymaBay Therapeutics Stock Trading
About | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
Not available
Quote | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
| Last: | $14.68 |
|---|---|
| Change Percent: | 0.6% |
| Open: | $14.82 |
| Close: | $14.68 |
| High: | $15.18 |
| Low: | $14.53 |
| Volume: | 1,364,255 |
| Last Trade Date Time: | 10/02/2023 03:00:00 am |
News | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
-
2023-09-26 16:29:38 ET More on Intercept Pharma Seeking Alpha’s Quant Rating on Intercept Pharma Intercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All Parties Intercept: Narrowed Market, Concentrated Strategy (Rating Upgrade) ...
-
2023-09-21 16:39:43 ET Shares of CymaBay Therapeutics (NASDAQ: CBAY) were sinking 11.3% lower this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence . The decline extended a sell-off that began last week following the b...
Message Board Posts | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
| Subject | By | Source | When |
|---|---|---|---|
| MomentumIts gaining up | jerseyboy | investorshub | 06/29/2023 10:29:09 PM |
| great news | oilin07 | investorshub | 06/27/2023 5:22:29 PM |
| what do you make of this data? | TonyJoe1957 | investorshub | 06/27/2023 12:33:09 AM |
| Anyone hear anything lately? Want to see this one go | swingingRichard | investorshub | 06/24/2023 5:09:53 PM |
| $CBAY The trading last trade up | swingingRichard | investorshub | 06/22/2023 2:55:50 PM |
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Ad
-
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar...
-
2023-09-21 16:39:43 ET Shares of CymaBay Therapeutics (NASDAQ: CBAY) were sinking 11.3% lower this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence . The decline extended a sell-off that began last week following the b...
-
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to support post-marketing regulatory requirements for seladelpar’s accelerated approval pathway NEWARK, Calif., Sept. 21, 2023 (GLOBE NEWSWIR...